Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A1 | P22736 | 1/20 | 0.56 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.56 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.56 |
| ▸ | MMP3 | P08254 | 1/20 | 0.50 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.50 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.48 |
| ▸ | CDC25B | P30305 | 1/20 | 0.48 |
| ▸ | PLK1 | P53350 | 1/20 | 0.48 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29393451 | 1.00 | NR4A1 (0.56) | NR4A1NR4A2NR4A3MMP3HDAC8 | |
| Hydrochloric Acid SCHEMBL5847290 | 0.98 | NR4A1 (0.54) | NR4A1NR4A2NR4A3MMP3HDAC8 | |
| SCHEMBL6956577 | 0.83 | NR4A1 (0.44) | NR4A1NR4A2NR4A3MMP3HDAC8 | |
| Hydrochloric Acid SCHEMBL28498400 | 0.81 | NR4A1 (0.42) | NR4A1NR4A2NR4A3MMP3HDAC8 | |
| SCHEMBL3233191 | 0.80 | NR4A1 (0.50) | NR4A1NR4A2NR4A3MMP3HDAC8 | |
| SCHEMBL23709157 | 0.80 | NR4A1 (0.60) | NR4A1NR4A2NR4A3MMP3HDAC8 | |
| SCHEMBL29381201 | 0.79 | KDM4E (0.68) | NR4A1NR4A2NR4A3MMP3HDAC8 | |
| SCHEMBL30627985 | 0.79 | L3MBTL1 (0.55) | NR4A1NR4A2NR4A3MMP3HDAC8 | |
| SCHEMBL28596381 | 0.79 | NR4A1 (0.54) | NR4A1NR4A2NR4A3MMP3HDAC8 | |
| SCHEMBL30849325 | 0.79 | NR4A1 (0.54) | NR4A1NR4A2NR4A3MMP3HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 158 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1907484-B1 | NAPHTHALENE AMIDINE IMIDES | BASF SE (DE) | 2010-09-29 | — | — | EP | claimed |
| EP-1907484-A1 | NAPHTHALENE AMIDINE IMIDES | Ciba Specialty Chemicals Holding, Inc. (CH) | 2008-04-09 | — | — | EP | claimed |
| CN-1972681-A | Systems and methods for transdermal delivery of anticoagulants | ALZA CORP (US) | 2007-05-30 | — | — | CN | claimed |
| EP-1758568-A1 | SYSTEM AND METHOD FOR TRANSDERMAL DELIVERY OF AN ANTICOAGULANT | Alza Corporation (US) | 2007-03-07 | — | — | EP | claimed |
| WO-2007012611-A1 | NAPHTHALENE AMIDINE IMIDES | CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) | 2007-02-01 | — | — | WO | claimed |
| WO-2005120482-A1 | SYSTEM AND METHOD FOR TRANSDERMAL DELIVERY OF AN ANTICOAGULANT | ALZA CORPORATION (US) | 2005-12-22 | — | — | WO | claimed |
| US-20050273047-A1 | System and method for transdermal delivery of an anticoagulant | ALZA CORPORATION | 2005-12-08 | — | — | US | claimed |
| EP-1276722-A1 | NAPHTHAMIDINE UROKINASE INHIBITORS | Abbott Laboratories (US) | 2003-01-22 | — | — | EP | claimed |
| WO-2001081314-A1 | NAPHTHAMIDINE UROKINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2001-11-01 | — | — | WO | claimed |
| US-20250188022-A1 | PROCESS FOR THE PREPARATION OF NAFAMOSTAT, CAMOSTAT AND THEIR DERIVATIVES | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2025-06-12 | — | — | US | disclosed |
| US-20240165106-A1 | POLYSUBUNIT OPIOID PRODRUGS RESISTANT TO OVERDOSE AND ABUSE | ELYSIUM THERAPEUTICS, INC. | 2024-05-23 | — | — | US | disclosed |
| US-11976051-B1 | N′-(2-(5-(4-chlorophenyl)-1,3,4-oxadiazol-2-ylthio)acetoxy)-2-naphthimidamide as an antimicrobial compound | King Faisal University (SA) | 2024-05-07 | — | — | US | disclosed |
| US-11905262-B1 | N′-(2-(5-(4-chlorophenyl)-1,3,4-oxadiazol-2-ylthio)acetoxy)-2-naphthimidamide as an antimicrobial compound | King Faisal University (SA) | 2024-02-20 | — | — | US | disclosed |
| US-20230241054-A1 | POLYSUBUNIT OPIOID PRODRUGS RESISTANT TO OVERDOSE AND ABUSE | ELYSIUM THERAPEUTICS, INC. | 2023-08-03 | — | — | US | disclosed |
| EP-0574545-A1 | PHENYL AMIDINES DERIVATIVES USEFUL AS PLATELET AGGREGATION INHIBITORS. | SEARLE & CO (US) | 1993-12-22 | — | — | EP | disclosed |
| WO-1992015607-A2 | PHENYL AMIDINES DERIVATIVES USEFUL AS PLATELET AGGREGATION INHIBITORS | G.D. SEARLE & CO. (US) | 1992-09-17 | — | — | WO | disclosed |
| EP-0343893-B1 | AROMATIC AND HETEROCYCLIC CARBOXAMIDE DERIVATIVES AS ANTINEOPLASTIC AGENTS | PFIZER INC. (US) | 1992-08-05 | — | — | EP | disclosed |
| US-4970318-A | ANTICARBINOGENIC AGENTS | PFIZER INC. (US) | 1990-11-13 | — | — | US | disclosed |
| CN-1037898-A | The preparation of aromatics and Heterocyclylcarboxamderivatives derivatives antineoplastic agent | PFIZER (US) | 1989-12-13 | — | — | CN | disclosed |
| EP-0343893-A1 | Aromatic and heterocyclic carboxamide derivatives as antineoplastic agents | PFIZER INC. (US) | 1989-11-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240165106-A1 | POLYSUBUNIT OPIOID PRODRUGS RESISTANT TO OVERDOSE AND ABUSE | OPRK1, OPRM1, CYP3A5 | NR4A1 4550/4885NR4A2 4724/4885NR4A3 4539/4885 |
| US-11905262-B1 | N′-(2-(5-(4-chlorophenyl)-1,3,4-oxadiazol-2-ylthio)acetoxy)-2-naphthimidamide as an antimicrobial compound | NIT2, NOC2L, B3GNT2 | NR4A1 493/4885NR4A2 408/4885NR4A3 716/4885 |
| US-20250188022-A1 | PROCESS FOR THE PREPARATION OF NAFAMOSTAT, CAMOSTAT AND THEIR DERIVATIVES | TPMT, ADH1C, ADH1A | NR4A1 1829/4885NR4A2 2160/4885NR4A3 2374/4885 |
| US-11976051-B1 | N′-(2-(5-(4-chlorophenyl)-1,3,4-oxadiazol-2-ylthio)acetoxy)-2-naphthimidamide as an antimicrobial compound | NIT2, NOC2L, B3GNT2 | NR4A1 581/4885NR4A2 460/4885NR4A3 795/4885 |
| US-20230241054-A1 | POLYSUBUNIT OPIOID PRODRUGS RESISTANT TO OVERDOSE AND ABUSE | OPRK1, OPRM1, CYP3A5 | NR4A1 4550/4885NR4A2 4724/4885NR4A3 4539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.